» Articles » PMID: 16880781

Evaluations of Biomarkers Associated with 5-FU Sensitivity for Non-small-cell Lung Cancer Patients Postoperatively Treated with UFT

Overview
Journal Br J Cancer
Specialty Oncology
Date 2006 Aug 2
PMID 16880781
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

The sensitivity to 5-fluorouracil (5-FU) has been reported to be associated with target molecule thymidylate synthase (TS), fluoropyrimidine-metabolising enzymes such as orotate phosphoribosyltransferase (OPRT), and dihydropyrimidine dehydrogenase (DPD). We performed an immunohistochemical study on the clinical significance of TS, OPRT, and DPD expression using 151 resected non-small-cell lung cancer (NSCLC) patients postoperatively treated with a combination of tegafur and uracil (UFT). Eighty-two carcinomas were TS-positive, 105 carcinomas were OPRT-positive, 68 carcinomas were DPD-positive. No correlation was observed in the HSCORE between the TS and OPRT expression (r=0.203), between the TS and DPD expression (r=0.098), or between the OPRT and DPD expression (r=0.074). Regarding the survival of NSCLC patients treated with UFT, the 5-year survival rate of patients with TS-negative tumours was significantly higher than that with TS-positive tumours (P=0.0133). The 5-year survival rate of patients with OPRT-positive stage II to III tumours was significantly higher than that with OPRT-negative stage II to III tumours (P=0.0145). In addition, the 5-year survival rate of patients with DPD-negative tumours was also significantly higher than that with DPD-positive tumours (P=0.0004). A Cox multivariate regression analysis revealed the TS status (hazard ratio 2.663; P=0.0003), OPRT status (hazard ratio 2.543; P=0.0005), and DPD status (hazard ratio 2.840; P<0.0001) to all be significant prognostic factors for the survival of resected NSCLC patients postoperatively treated with UFT.

Citing Articles

5FU encapsulated polyglycerol sebacate nanoparticles as anti-cancer drug carriers.

Sivanesan D, Verma R, Prasad E RSC Adv. 2022; 11(31):18984-18993.

PMID: 35478658 PMC: 9033480. DOI: 10.1039/d1ra01722e.


Intratumoral gene expression of dihydrofolate reductase and folylpoly-c-glutamate synthetase affects the sensitivity to 5-fluorouracil in non-small cell lung cancer.

Sakon K, Sasaki M, Tanaka K, Mizunaga T, Yano K, Kawamura Y Discov Oncol. 2022; 12(1):19.

PMID: 35201464 PMC: 8777502. DOI: 10.1007/s12672-021-00413-w.


Salvage Chemotherapy in Patients with Previously Treated Thymic Carcinoma.

Kaira K, Imai H, Yamaguchi O, Mouri A, Kagamu H Cancers (Basel). 2021; 13(21).

PMID: 34771601 PMC: 8582353. DOI: 10.3390/cancers13215441.


Clinical Significance of Various Drug-Sensitivity Markers in Patients with Surgically Resected Pulmonary Pleomorphic Carcinoma.

Imai H, Shimizu K, Kawashima O, Endoh H, Imaizumi K, Goto Y Cancers (Basel). 2019; 11(11).

PMID: 31653009 PMC: 6895922. DOI: 10.3390/cancers11111636.


Thymidine phosphorylase affects clinical outcome following surgery and mRNA expression levels of four key enzymes for 5-fluorouracil metabolism in patients with stage I and II non-small cell lung cancer.

Himuro N, Niiya Y, Minakata T, Oshima Y, Kataoka D, Yamamoto S Mol Clin Oncol. 2018; 9(6):640-646.

PMID: 30546894 PMC: 6256090. DOI: 10.3892/mco.2018.1726.


References
1.
Peters G, Laurensse E, Leyva A, Lankelma J, Pinedo H . Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res. 1986; 46(1):20-8. View

2.
Higashiyama M, Kodama K, Yokouchi H, Takami K, Fukushima M, Minamigawa K . Thymidylate synthase and dihydropyrimidine dehydrogenase activities in non-small cell lung cancer tissues: relationship with in vitro sensitivity to 5-fluorouracil. Lung Cancer. 2001; 34(3):407-16. DOI: 10.1016/s0169-5002(01)00248-3. View

3.
Dautzenberg B, Arriagada R, Chammard A, Jarema A, Mezzetti M, Mattson K . A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Groupe d'Etude et de Traitement des Cancers Bronchiques. Cancer. 1999; 86(2):265-73. DOI: 10.1002/(sici)1097-0142(19990715)86:2<265::aid-cncr10>3.0.co;2-b. View

4.
Rocco P, Antkowiak J, Takita H, Urschel J . Long-term outcome after pneumonectomy for nonsmall cell lung cancer. J Surg Oncol. 1996; 61(4):278-80. DOI: 10.1002/(SICI)1096-9098(199604)61:4<278::AID-JSO9>3.0.CO;2-7. View

5.
Beck A, Etienne M, Cheradame S, Fischel J, Formento P, Renee N . A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer. 1994; 30A(10):1517-22. DOI: 10.1016/0959-8049(94)00216-r. View